BBPL, based in Columbia, Missouri, is a provider a diagnostic and clinical laboratory services in the Midwest.
“This relationship will extend our ability to provide the most innovative, cost-efficient services to patients and providers in the nation’s heartland, deepening our presence in the region,” Steve Rusckowski, chairman, CEO and president, Quest Diagnostics, said. “It is consistent with our accelerate growth strategy, which includes delivering 1 to 2 percent in annual revenue through strategically aligned accretive acquisitions.”
BBPL’s anatomic pathology division, Boyce and Bynum Pathology Professional Services Inc., and long-term care division are not part of the deal, BBPL said.
Through a separate agreement, BBPPS will become the pathology provider for Quest Diagnostic clients in Missouri. The agreement will go into effect once the BBPL deal is completed, which is expected in the first quarter of 2019.
“BBPL and Quest have complementary strengths that will improve access to superior diagnostic innovation by combining the anatomic pathology capabilities and clinical expertise of BBPPS and Quest,” Michael D. Curry, CEO, president and medical director, BBPL, said. “We are confident that Quest is the right organization to build on the progress and vision of BBPL to empower better health for patients in the Midwest.”